COMPARISON OF VARIOUS CORRELATION ON IRMA FOR CA19-9 AND CA50 IN THE DIGESTIVE SYSTEM TUMOUR

Mo Qizhong，

R.P. Baum，

A. Hertel，

G. Hör

Nuclear Science and Techniques

Vol.1, No.4

pp.234-238

Published in print 01 Nov 1990

32700

This paper compared various correlation of IMRA for CA19- 9 and CA50 in the digestive system tumour antigen, such as linearity, sensitivity, analytical range, precision as well as storage and stability and so on. And it also determined serum level of CA19- 9 and CA50 of patients with different tumours. The results showed it was well correlated to CA19- 9 and CA50 as a marker of digestive system tumour. Particularly high levels of both markers were found in patients with pancreastic colonic cancer. Therefore it is possible to obtain a higher sensitivity and acceptable specificity by combination with CA19- 9 and CA50.

Tumour markerCA50CA19- 9IRMASolid phase immunoassayInter- and intraassay variance

REFERENCES

[1]

H. Koprowski et al., Somat Cell. Genet, 5 (1979), 957.

[2]

Lindholm et al., Int. Arch. Allergy Appl. Immun. 71 (1983), 178.

[3]

J.L. Magnani et al., J. Biol. Chem., 257 (1982), 14365.

[4]

J.E. Mansson et al., Biochem. Biophy. Acta, 834 (1985), 110.

[5]

O. Nilsson et al., FEBS Lett., 182 (1985), 398.

[6]

R.E. Ritts et al., Int. J. Cancer, 33 (1984), 339.

[7]

C. Haglund et al., Brit. J., Cancer, 53 (1986), 197.

[8]

J. Holmgren et al., Brit. Med. J., 288 (1984), 1479.

[9]

C. Haglund et al., Int. J. Cancer, 39 (1987), 477.

[10]

C. Haglund et al., Brit. J. Cancer, 53 (1986), 189.

[11]

C. Haglund et al., Int. J. Cancer, 38 (1986), 841.

[12]

R.P. Baum et al., Radiolabeled monoclonal antibody for imaging and therapy, Pergamo press, New York, 1988.

[13]

R.P. Baum et al., Int. J. Biol. Marker, 3 (1988), 177.

[14]

A. Lamiquiz Vallejo et al., Int. J. Biol. Marker, 3 (1988), 206.